Stockreport

Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF trials in parallel for Haduvio in IPF-related chronic cough: a global 52-week study (~ 300 patients ) starting in Q2 2026 with a 24-week primary readout, and a smaller c [Read more]